Session » Late-Breaking Abstracts (L01–L06)
- 9:00AM-10:30AM
-
Abstract Number: L03
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
- 9:00AM-10:30AM
-
Abstract Number: L02
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
- 9:00AM-10:30AM
-
Abstract Number: L05
Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase
- 9:00AM-10:30AM
-
Abstract Number: L01
Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study
- 9:00AM-10:30AM
-
Abstract Number: L04
Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis